ImmuPharma plc (LON:IMM – Get Free Report) dropped 10.1% on Tuesday . The company traded as low as GBX 3.22 ($0.04) and last traded at GBX 3.37 ($0.04). Approximately 8,361,791 shares traded hands during trading, a decline of 70% from the average daily volume of 27,776,645 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Stock Performance
The firm has a 50 day moving average price of GBX 1.54 and a two-hundred day moving average price of GBX 1.68. The company has a market capitalization of £10.24 million, a P/E ratio of -246.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- What is a support level?
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- ESG Stocks, What Investors Should Know
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- High Flyers: 3 Natural Gas Stocks for March 2022
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
